CR10764A - Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato - Google Patents

Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato

Info

Publication number
CR10764A
CR10764A CR10764A CR10764A CR10764A CR 10764 A CR10764 A CR 10764A CR 10764 A CR10764 A CR 10764A CR 10764 A CR10764 A CR 10764A CR 10764 A CR10764 A CR 10764A
Authority
CR
Costa Rica
Prior art keywords
crystal
chlorophenyl
novedoso
hydroxyethyl carbamate
carbamate
Prior art date
Application number
CR10764A
Other languages
English (en)
Inventor
Peterson Matthew
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR10764A publication Critical patent/CR10764A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

La presente invencion se relaciona con un cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato, composiciones farmaceuticas que comprenden este cristal y metodos para elaborar y utilizar este cristal.
CR10764A 2006-10-06 2009-05-05 Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato CR10764A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82839206P 2006-10-06 2006-10-06

Publications (1)

Publication Number Publication Date
CR10764A true CR10764A (es) 2009-09-14

Family

ID=39283405

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10764A CR10764A (es) 2006-10-06 2009-05-05 Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato

Country Status (19)

Country Link
US (1) US7632963B2 (es)
EP (1) EP2076258A4 (es)
JP (1) JP2010505856A (es)
KR (1) KR20090076958A (es)
CN (1) CN101657195A (es)
AU (1) AU2007307029A1 (es)
BR (1) BRPI0718131A2 (es)
CA (1) CA2665573A1 (es)
CO (1) CO6180504A2 (es)
CR (1) CR10764A (es)
EA (1) EA200970355A1 (es)
GT (1) GT200900076A (es)
IL (1) IL198016A0 (es)
MX (1) MX2009003755A (es)
NI (1) NI200900050A (es)
NO (1) NO20091771L (es)
SV (1) SV2009003211A (es)
WO (1) WO2008045391A2 (es)
ZA (1) ZA200903095B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
KR101795562B1 (ko) * 2011-12-27 2017-11-08 (주)바이오팜솔루션즈 뇌졸중의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
WO2023014160A1 (ko) * 2021-08-05 2023-02-09 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법
KR102399807B1 (ko) * 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
CN1176654C (zh) * 1999-09-10 2004-11-24 大日本油墨化学工业株式会社 喹啉酮衍生物制剂及其制法
IL157591A0 (en) * 2001-02-27 2004-03-28 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neurodegenerative disorders
CZ2004718A3 (cs) * 2001-12-21 2004-12-15 Ortho-Mc-Neil Pharmaceutical, Inc. Způsob přípravy 2-(substituovaný fenyl)-2-hydroxyethylkarbamátů
PL1658277T3 (pl) * 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
HRP20100304T1 (hr) * 2004-09-16 2010-09-30 Janssen Pharmaceutica Nv Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Also Published As

Publication number Publication date
MX2009003755A (es) 2009-07-10
SV2009003211A (es) 2009-11-24
EA200970355A1 (ru) 2009-12-30
IL198016A0 (en) 2009-12-24
NI200900050A (es) 2010-02-01
WO2008045391A3 (en) 2008-06-12
EP2076258A2 (en) 2009-07-08
CA2665573A1 (en) 2008-04-17
ZA200903095B (en) 2010-07-28
US7632963B2 (en) 2009-12-15
BRPI0718131A2 (pt) 2013-11-05
CN101657195A (zh) 2010-02-24
WO2008045391A2 (en) 2008-04-17
GT200900076A (es) 2010-05-18
CO6180504A2 (es) 2010-07-19
US20080085930A1 (en) 2008-04-10
KR20090076958A (ko) 2009-07-13
EP2076258A4 (en) 2011-09-28
NO20091771L (no) 2009-05-05
AU2007307029A1 (en) 2008-04-17
JP2010505856A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
CR10479A (es) Modulares bencimidazolicos de vr1
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
HN2007000407A (es) Compuesto de biaril eter urea
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
CR9569A (es) Modificaciones cristalinas de la piraclostrobina
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY33735A (es) Compuestos antivirales
BRPI0509184A (pt) composições farmacêuticas
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
CR10766A (es) Inhibidores de metaloproteasa derivados de heterociclicos
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
TW200621313A (en) Pharmaceutical compositions
HN2006037713A (es) Compuestos utiles en terapia
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
NI200900050A (es) Nuevo cristal de (s)-(+)-2-(2-clorofenil)-2-hidroxi-etil carbamato
GT200500130A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
HN2006029142A (es) Proceso
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
GT200500358A (es) Compuestos organicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)